DK0649464T3 - Transfektion af vertebratceller, eksempelvis ved homolog rekombination - Google Patents

Transfektion af vertebratceller, eksempelvis ved homolog rekombination

Info

Publication number
DK0649464T3
DK0649464T3 DK92924367.3T DK92924367T DK0649464T3 DK 0649464 T3 DK0649464 T3 DK 0649464T3 DK 92924367 T DK92924367 T DK 92924367T DK 0649464 T3 DK0649464 T3 DK 0649464T3
Authority
DK
Denmark
Prior art keywords
cells
product
transfected
primary
dna
Prior art date
Application number
DK92924367.3T
Other languages
English (en)
Inventor
Richard F Selden
Michael W Heartlein
Douglas A Treco
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0649464(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Application granted granted Critical
Publication of DK0649464T3 publication Critical patent/DK0649464T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
DK92924367.3T 1991-11-05 1992-11-05 Transfektion af vertebratceller, eksempelvis ved homolog rekombination DK0649464T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78784091A 1991-11-05 1991-11-05
US78918891A 1991-11-05 1991-11-05
US91153392A 1992-07-10 1992-07-10

Publications (1)

Publication Number Publication Date
DK0649464T3 true DK0649464T3 (da) 1998-03-02

Family

ID=27419842

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92924367.3T DK0649464T3 (da) 1991-11-05 1992-11-05 Transfektion af vertebratceller, eksempelvis ved homolog rekombination
DK96202037T DK0750044T3 (da) 1991-11-05 1992-11-05 DNA-konstruktioner og transfektion af celler dermed til homolog rekombination

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK96202037T DK0750044T3 (da) 1991-11-05 1992-11-05 DNA-konstruktioner og transfektion af celler dermed til homolog rekombination

Country Status (18)

Country Link
US (7) US5994127A (da)
EP (3) EP0750044B1 (da)
JP (3) JP3564126B2 (da)
KR (1) KR100339316B1 (da)
AT (2) ATE155810T1 (da)
AU (1) AU669499B2 (da)
CA (1) CA2122991A1 (da)
DE (2) DE69221168T2 (da)
DK (2) DK0649464T3 (da)
ES (2) ES2106891T3 (da)
GR (1) GR3025054T3 (da)
IL (1) IL103649A0 (da)
MX (1) MX9206376A (da)
MY (1) MY119132A (da)
NZ (1) NZ245015A (da)
PT (1) PT101031B (da)
SG (1) SG44652A1 (da)
WO (1) WO1993009222A2 (da)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094400B1 (en) * 1987-05-01 2006-08-22 Shire Human Genetic Therapies, Inc. Transkaryotic implantation
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5538722A (en) * 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
ATE174058T1 (de) * 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
HU217212B (hu) 1989-12-22 1999-12-28 Applied Research Systems, ARS Holding M.V. Endogén gének expressziójának módosítása szabályozóelemmel
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
EP0695361B2 (en) * 1993-04-21 2009-11-11 The University Court Of The University Of Edinburgh Expression of heterologous genes according to a targeted expression profile
SE9402642D0 (sv) * 1994-08-05 1994-08-05 Maria Anvret Gene Therapy
US6419920B1 (en) 1995-10-25 2002-07-16 Trans Karyotic Therapies, Inc. Hybrid matrix implants and explants
US5965125A (en) 1995-10-25 1999-10-12 Transkaryotic Therapies, Inc. Hybrid matrix implants and explants
US5869041A (en) * 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
WO1997029180A1 (en) * 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
PT1538202E (pt) 1996-09-13 2014-04-22 Shire Human Genetic Therapies Produção de alga-galactosidase a humana
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
CN1254376A (zh) 1996-10-01 2000-05-24 杰龙公司 端粒酶逆转录酶
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
BR9808584A (pt) 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US6172211B1 (en) 1997-07-11 2001-01-09 Boehringer Ingelheim International Gmbh Nucleic acid encoding tag7 polypeptide
PT1000154E (pt) 1997-07-23 2007-03-30 Roche Diagnostics Gmbh Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes
US6391633B1 (en) 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
WO1999005267A1 (de) * 1997-07-23 1999-02-04 Roche Diagnostics Gmbh Identifizierung humaner zellinien zur produktion humaner proteine durch endogene genaktivierung
ATE341625T1 (de) * 1997-07-23 2006-10-15 Roche Diagnostics Gmbh Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US7316923B1 (en) 1997-09-26 2008-01-08 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
ZA989497B (en) † 1997-10-20 2000-04-19 Roche Diagnostics Gmbh Positive-negative selection in homologous recombination.
TR200001580T2 (tr) 1997-12-03 2000-12-21 Roche Diagnostics Gmbh Spesifik etkinliği yüksek eritropoyetin
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
EP1071768B1 (en) * 1998-04-24 2004-12-29 Transkaryotic Therapies, Inc. Delivery of therapeutic proteins via implantation of genetically modified cells in the omentum
US6537806B1 (en) * 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
ATE369877T1 (de) * 1998-06-26 2007-09-15 Genetronics Inc Synergismus von photodynamischen und elektropermeationseffekten auf die zellvitalität als ein neues cytotoxisches mittel
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
WO2000002620A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
WO2000032750A1 (en) 1998-11-24 2000-06-08 Regents Of The University Of Minnesota Transgenic circulating endothelial cells
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
ATE377077T1 (de) 1999-04-28 2007-11-15 Genetics Inst Llc Humane gil-19/ae289 proteine und dafür kodierende polynukleotide
EP1054018B1 (en) 1999-05-18 2009-01-28 Dyax Corp. Fab fragment libraries and methods for their use
DE60040678D1 (en) 1999-09-29 2008-12-11 Gen Hospital Corp Parathyroid hormon (pth) polypeptidderivate
JP2003514532A (ja) * 1999-11-19 2003-04-22 トランスカーヨティック セラピーズ インコーポレイテッド 生成物の産生量を最適化するための核酸構築体
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
EP1728862A1 (en) 2000-03-16 2006-12-06 Genetica, Inc. Methods and compositions for RNA interference
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6686188B2 (en) * 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US6656700B2 (en) * 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
KR100407792B1 (ko) * 2000-08-02 2003-12-01 한국생명공학연구원 인간 글루카곤 유사펩타이드를 융합파트너로 이용한재조합 단백질의 제조방법
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002022151A2 (en) 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
DE60144439D1 (de) 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
WO2002072790A2 (en) 2001-03-14 2002-09-19 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP2003451B1 (en) 2001-06-26 2012-05-30 Senomyx, Inc. T1r1-t1r3 hetero-oligomeric umami taste receptors and cell lines that express said receptors and use thereof for identification of umami taste compounds
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
JP4551656B2 (ja) 2001-07-10 2010-09-29 セノミックス インコーポレイテッド 苦味を阻止する化合物を同定するための特異的ｔ２ｒ味覚受容体の使用
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
AU2002322720B2 (en) * 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20040078837A1 (en) * 2001-08-02 2004-04-22 Shannon Mark E. Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
MXPA04004534A (es) * 2001-11-16 2004-08-11 Childrens Medical Center Aumento de la funcion de un organo.
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
CN1296485C (zh) 2002-01-17 2007-01-24 英国龙沙生物医药股份有限公司 能够产生蛋白质及能够在无谷氨酰胺的培养基上生长的谷氨酰胺营养缺陷型人类细胞
EP1585386A4 (en) 2002-02-20 2009-09-02 American Integrated Biolog Inc GENE PRODUCTION IN SALIVA
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
BR122017016940B8 (pt) 2002-04-25 2021-07-27 Transkaryotic Therapies Inc método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a
US7374930B2 (en) * 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
JP2006517101A (ja) * 2003-01-13 2006-07-20 エス． ラオ、マヘンドラ 治療用産物を送達するための、増殖性の幹細胞および前駆細胞における候補分子の持続的発現
WO2004064785A2 (en) 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
JP2007512227A (ja) 2003-08-06 2007-05-17 セノミックス、インコーポレイテッド Ｔ１ｒヘテロオリゴマー味覚受容体、この受容体を発現する細胞株、および味覚化合物
JP2007514673A (ja) * 2003-12-19 2007-06-07 エフ．ホフマン−ラ　ロシュ　アーゲー 慢性炎症性腸疾患の際の鉄分布障害の処置におけるエリスロポエチンの使用
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
EP2338994B1 (en) 2004-09-02 2014-03-19 Yale University Regulation of oncogenes by microRNAs
AU2006247065B8 (en) 2005-05-17 2012-07-12 Amicus Therapeutics, Inc. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
WO2007002528A1 (en) 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
AU2006287315B2 (en) 2005-09-09 2013-02-21 The Johns Hopkins University Manipulation of regulatory T cell and DC function by targeting neuritin gene using antibodies, agonists and antagonists
MX2007015931A (es) 2005-10-20 2008-04-22 Senomyx Inc Receptores de sabor dulce-umami y umami-dulce humanos quimericos.
RU2008115455A (ru) 2005-11-03 2009-12-10 Рэдпойнт Био Корпорэйшн (Us) Высокопроизводительный скрининг-анализ ионного канала trpm5
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
EP3235811B1 (en) 2006-04-21 2018-07-25 Senomyx, Inc. Process of preparing oxalamides
JP2007325571A (ja) * 2006-06-09 2007-12-20 Toto Ltd 組換え哺乳類動物細胞を用いたタンパク質生産方法
WO2007150069A2 (en) 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
CN101687009A (zh) 2007-05-11 2010-03-31 宾夕法尼亚大学理事会 治疗皮肤溃疡的方法
KR101730290B1 (ko) 2007-05-11 2017-04-25 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
US9580688B2 (en) * 2007-06-08 2017-02-28 Wake Forest University Health Sciences Kidney structures and methods of forming the same
CA2688265C (en) * 2007-06-08 2021-02-16 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US10590391B2 (en) * 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
EP2006388A1 (de) * 2007-06-19 2008-12-24 Helmholtz-Zentrum für Infektionsforschung GmbH Nukleinsäurekonstrukte zur Inaktivierung und konditionalen Mutagenese von Genen
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
CN101784281B (zh) 2007-08-01 2014-07-02 总医院有限公司 确定g蛋白偶联受体激动剂的方法
JP4997253B2 (ja) * 2007-08-10 2012-08-08 Ｔｏｔｏ株式会社 組換え哺乳動物細胞、組換え哺乳動物細胞の製造方法、および目的タンパク質の生産方法
ES2545121T3 (es) 2007-08-21 2015-09-08 Senomyx, Inc. Compuestos que inhiben (bloquean) el sabor amargo en composiciones, y uso de los mismos
WO2009079399A2 (en) * 2007-12-14 2009-06-25 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
EP2245145B1 (en) 2008-01-18 2016-12-14 BioMarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
US8110185B2 (en) 2008-10-03 2012-02-07 St. Michael's Hospital Method for preventing and treating cardiovascular diseases with BRCA1
EP2358375B1 (en) * 2008-11-12 2013-07-24 Tengion, Inc. Isolated renal cells and uses thereof
US20100178641A1 (en) * 2009-01-12 2010-07-15 Franklin David Damon Apparel fastening learning apparatus
US8211655B2 (en) 2009-02-12 2012-07-03 Discoverx Corporation Wild-type receptor assays
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
EA022396B1 (ru) 2009-09-23 2015-12-30 Ратиофарм Гмбх Способ очистки рекомбинантного эритропоэтина человека (epo), эритропоэтин, очищенный данным способом, и фармацевтические композиции, содержащие такой эритропоэтин
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
RU2566267C2 (ru) 2010-09-14 2015-10-20 Ф. Хоффманн-Ля Рош Аг Способ очистки пегилированного эритропоэтина
KR102302069B1 (ko) 2010-11-10 2021-09-14 인리젠 장기 확대를 위한 주사가능 제제
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
EP2739734A1 (en) 2011-08-03 2014-06-11 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Treatment of fibrosis using microrna-19b
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
EP2970420A4 (en) 2013-03-15 2016-08-17 Apotex Inc STABILITY OF THE ENHANCED LIQUID FORMULATION OF ERYTHROPOIETIN ALPHA VIA A PURIFICATION TREATMENT
US10196601B2 (en) 2013-08-20 2019-02-05 Lek Pharmaceuticals D.D. Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides
KR102473092B1 (ko) 2014-09-15 2022-12-01 칠드런'즈 메디컬 센터 코포레이션 히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
MA40871A (fr) 2014-10-29 2017-09-05 Novartis Ag Expression directe d'anticorps
AU2017295037B2 (en) 2016-07-15 2021-07-22 F. Hoffmann-La Roche Ag Method for purifying PEGylated erythropoietin
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
JP7410860B2 (ja) 2017-12-29 2024-01-10 エフ． ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法
JP7137625B2 (ja) 2017-12-29 2022-09-14 エフ．ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法
HRP20220388T1 (hr) 2017-12-29 2022-05-27 F. Hoffmann - La Roche Ag Postupak za dobivanje pegiliranog proteinskog pripravka
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
CN115210361B (zh) * 2020-03-04 2024-12-10 淋巴奥格尼克斯有限公司 促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024129459A1 (en) 2022-12-16 2024-06-20 University Of Rochester Repairmen! of barrier dysfunction in esophagus
WO2025259466A1 (en) 2024-06-13 2025-12-18 University Of Rochester Gm-csf and gm-csf-induced dendritic cells enhance fracture healing and bone repair

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4396601A (en) * 1980-03-26 1983-08-02 The Regents Of The University Of Calif. Gene transfer in intact mammals
DE3176404D1 (en) * 1980-04-22 1987-10-08 Pasteur Institut Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
ATE89314T1 (de) * 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
AU6131086A (en) * 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3789678T2 (de) * 1986-02-27 1994-08-11 Snow Brand Milk Prod Co Ltd Herstellung von erythropoietinproduzierenden Zellen und Verfahren zur Herstellung von Erythropoietin mit Verwendung dieser Zellen.
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5175255A (en) * 1987-03-23 1992-12-29 Amgen Inc. Methods for purification of platelet-derived growth factor
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
DE3855681T2 (de) * 1987-05-01 1997-05-28 The General Hospital Corp., Boston, Mass. Transkaryotische Einpflanzung
US5166059A (en) * 1987-06-16 1992-11-24 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy using gene fusions for genetic or acquired disorders
WO1989000239A1 (fr) * 1987-07-06 1989-01-12 Komatsu Zenoah Kabushiki Kaisha Starter pour moteurs
GB8718779D0 (en) * 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
DE3852823T2 (de) * 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
JP2914692B2 (ja) * 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
US4890286A (en) * 1987-12-11 1989-12-26 Sanyo Electric Co., Ltd. Method and apparatus for decoding error correcting code
DE3802640A1 (de) * 1988-01-29 1989-08-03 Roehm Gmbh Haarerhaltendes aescherverfahren
EP0400047B1 (en) * 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
WO1990006997A1 (en) * 1988-12-13 1990-06-28 United States Government As Represented By The Secretary Of The Department Of Health And Human Services Genetically engineered endothelial cells and use thereof
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
HU9203905D0 (en) * 1989-04-05 1993-04-28 Glaxo Group Ltd Method for producing ranitidine
GB8909218D0 (en) * 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
EP0457856A4 (en) * 1989-06-13 1992-10-21 The Board Of Directors Of The Leland Stanford Junior University Isolation growth and differentiation of human muscle cells
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
ATE174058T1 (de) * 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
HU217212B (hu) * 1989-12-22 1999-12-28 Applied Research Systems, ARS Holding M.V. Endogén gének expressziójának módosítása szabályozóelemmel
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991013151A1 (en) * 1990-02-22 1991-09-05 Biogen, Inc. Improved expression of polypeptides
IT1241123B (it) * 1990-04-19 1993-12-29 Consiglio Nazionale Ricerche Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
AU654284B2 (en) * 1990-06-12 1994-11-03 Baylor College Of Medicine Method for homologous recombination in animal and plant cells
DE69133557D1 (de) * 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
EP0556345B2 (en) * 1990-10-31 2005-10-12 Cell Genesys, Inc. Retroviral vectors useful for gene therapy
WO1992008796A1 (en) * 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
JPH05505944A (ja) * 1990-12-26 1993-09-02 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 修飾肝細胞およびその用途
WO1992015676A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Somatic cell gene therapy
DE69233387T2 (de) * 1991-05-06 2005-07-21 Cell Genesys, Inc., Foster City Genmanipulation und Expression mittels genomischer Elemente
AU664847B2 (en) * 1991-05-15 1995-12-07 Cell Genesys, Inc. Genomic modifications with homologous DNA targeting
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6670178B1 (en) * 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) * 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
KR960037062A (ko) * 1996-08-02 1996-11-19 오동덕 화농성 피부질환 치료제의 제조방법

Also Published As

Publication number Publication date
AU669499B2 (en) 1996-06-13
JP3564126B2 (ja) 2004-09-08
MX9206376A (es) 1994-02-28
SG44652A1 (en) 1997-12-19
EP0750044A3 (en) 1997-01-15
JPH07500969A (ja) 1995-02-02
PT101031A (pt) 1994-02-28
US6048524A (en) 2000-04-11
US20050136041A1 (en) 2005-06-23
CA2122991A1 (en) 1993-05-13
NZ245015A (en) 1995-12-21
DE69221168D1 (de) 1997-09-04
US6355241B1 (en) 2002-03-12
EP1221477A2 (en) 2002-07-10
DE69232728D1 (de) 2002-09-12
EP0649464A1 (en) 1995-04-26
EP0750044B1 (en) 2002-08-07
JP2005046147A (ja) 2005-02-24
ATE155810T1 (de) 1997-08-15
WO1993009222A2 (en) 1993-05-13
AU3069892A (en) 1993-06-07
US20020155597A1 (en) 2002-10-24
ES2181841T3 (es) 2003-03-01
EP1221477A3 (en) 2002-07-24
KR100339316B1 (da) 2005-01-15
HK1014033A1 (en) 1999-09-17
JP3733110B2 (ja) 2006-01-11
PT101031B (pt) 2002-07-31
US20100143314A1 (en) 2010-06-10
EP0649464B1 (en) 1997-07-23
DE69232728T2 (de) 2003-04-03
ATE221917T1 (de) 2002-08-15
DE69221168T2 (de) 1998-02-26
US5994127A (en) 1999-11-30
JP2003174897A (ja) 2003-06-24
EP0750044A2 (en) 1996-12-27
WO1993009222A3 (en) 1993-10-28
US6846676B2 (en) 2005-01-25
DK0750044T3 (da) 2002-12-02
GR3025054T3 (en) 1998-01-30
US7410799B2 (en) 2008-08-12
ES2106891T3 (es) 1997-11-16
MY119132A (en) 2005-04-30
IL103649A0 (en) 1993-04-04
US6048724A (en) 2000-04-11

Similar Documents

Publication Publication Date Title
KR100339316B1 (da)
MY140230A (en) Activating expression of an amplifying endogenous gene by homologous recombination
JP4562915B2 (ja) サイクリンｄ１の過剰発現により媒介される真核細胞内での所望のタンパク質の過剰発現
US5354674A (en) Method of gene transfer using retrotransposons
CN101591653B (zh) 低表达cyp7a1的肝细胞及其构建方法
Michel et al. Long-term in vivo and in vitro AAV-2-mediated RNA interference in rat retinal ganglion cells and cultured primary neurons
Gagnoux‐Palacios et al. Assessment of optimal transduction of primary human skin keratinocytes by viral vectors
CN119053694B (zh) 一种分离的转座酶及其用途
CN120535610A (zh) 重组xvii型胶原蛋白及其应用
Li et al. Retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines
JP5858393B2 (ja) 抗体の可変領域を用いた新規な遺伝子発現調節方法
Chande et al. Multiple platforms of a HIV-2 derived lentiviral vector for expanded utility
CN106554943A (zh) 一种重组过表达Creb3L1基因的CHO细胞株CHO-Creb3L1
US20250270522A1 (en) Isolated transposase and use thereof
EP3891288B1 (en) Matrix attachment regions and uses in promoting gene expression
EP4400585A1 (en) System for regulating protein translation
Min et al. Workflows for stable cell line generation: Chemical transfection and viral transduction
CN121160708A (zh) 一种atg13基因及其在提高外源重组蛋白表达中的应用
Oberbek et al. Lentiviral vectors for rapid and efficient recombinant CHO cell line generation
Girard et al. Scalable, Serum-Free, High Efficiency Transfection of CHO Cells Using an Economical DNA Transfer Vehicle
Moreau-Toussaint et al. Efficient mRNA Delivery in difficult-to-transfect cells with jetMESSENGER® Transfection Reagent
Diamond DEVELOPMENT OF AN IN VITRO SYSTEM FOR STUDYING DNA RECOMBINATION IN MAMMALIAN CELLS.
Gonos Organization and In Vitro Expression of Human tRNAGlu Genes